賽爾奈微生醫股份有限公司
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
We are the first commercial platform to utilize a Patient-Derived Explants (PDEs) platform to evaluate and select cancer immunotherapy responses by developing single-cell functional multi-omics analysis modules. Cell Envision accelerates the identification of disease etiology and discovery in oncology by revealing the true functional biology of each patient's cells.
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2022
Unified Business No.
90130905
Status
Active
Number of Employees
0
Total Paid-in
Capital
5,270,000 (NT$)
Location of Company
Taiwan
, Hsinchu City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
賽爾奈微生醫 originates from the Biomedical Center of Tsing Hua University. In addition to continuously advancing in the field of scientific research and publishing multiple research papers and achievements in domestic and international journals, we also maintain collaborations with authoritative Taiwanese institutions such as Academia Sinica and the National Health Research Institutes, contributing our efforts to cancer research in Taiwan.
In recent years, we have also begun to venture into the field of clinical services, providing hospitals, health examination centers, and physicians with better early detection tools, hoping to benefit more patients and their families, and helping more people detect risks early for timely treatment and recovery!
(The content above was translated by AI.)
In recent years, we have also begun to venture into the field of clinical services, providing hospitals, health examination centers, and physicians with better early detection tools, hoping to benefit more patients and their families, and helping more people detect risks early for timely treatment and recovery!
(The content above was translated by AI.)
